Angiogenesis inhibition by the maleimide-based small molecule GNX-686

Microvascular Research

Volumn 83, Issue 2, 2012, Pages 105-110

  Nowak Sliwinska, Patrycja ^a   Storto, Mariangela ^b   Cataudella, Tiziana ^c   Ballini, Jean Pierre ^a   Gatz, Randall ^d   Giorgio, Marco ^e   van den Bergh, Hubert ^a   Plyte, Simon ^b   Wagnières, Georges ^a  

^a EPFL   (Switzerland)

^b Congenia Srl ^*  (Italy)

^c DAC Research   (Italy)

^d OphthalmoPharma Ltd   (Switzerland)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; GNX 686; MALEIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ARTICLE; CELL CULTURE; CELL GROWTH; CELL NUCLEUS; CHICK EMBRYO; CHORIOALLANTOIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SENSITIVITY; EMBRYO; FIBROBLAST; GROWTH INHIBITION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULATURE; MORPHOLOGY; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RETINA BLOOD VESSEL; RETINA NEOVASCULARIZATION; RETROLENTAL FIBROPLASIA; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANIMALS, NEWBORN; ANTIBODIES, MONOCLONAL, HUMANIZED; CELL PROLIFERATION; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; HELA CELLS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; INFANT, NEWBORN; MALEIMIDES; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PHYSIOLOGIC; RETINAL NEOVASCULARIZATION; RETINOPATHY OF PREMATURITY;

MUS;

EID: 84856777866     PISSN: 00262862     EISSN: 10959319     Source Type: Journal    
DOI: 10.1016/j.mvr.2011.10.004     Document Type: Article

References (33)

1. Acharya N., Young L. Sustained-release drug implants for the treatment of intraocular disease. Int. Ophthalmol. Clin. 2004, 44:33-39.
2. Afzal A., et al. Targeting retinal and choroid neovascularization using the small molecule inhibitor carboxyamidotriazole. Brain Res. Bull. 2010, 81:320-326.
3. Ali Y., Lehmussaari K. Industrial perspective in ocular drug delivery. Adv. Drug Deliv. Rev. 2006, 58:1258-1268.
4. Ambati J., et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv. Ophthalmol. 2003, 48:257-293.
5. American Academy of Ophthalmology Photodynamic therapy with verteporfin for age-related macular degeneration. Ophthalmology 2000, 107:2314-2317.
6. Apte R.S., et al. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration. Ophthalmology 2007, 114:1702-1712.
7. Becerra E.M., et al. Clinical evidence of intravitreal triamcinolone acetonide in the management of age-related macular degeneration. Curr. Drug Targets 2011, 12:149-172.
8. Biswas P., et al. Comparing ranibizumab with bevacizumab. Ophthalmology 2011, 118(600-600):e2.
9. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
10. Cheung N., et al. Diabetic retinopathy. Lancet 2010, 376:124-136.
11. Chiang A., Regillo C.D. Preferred therapies for neovascular age-related macular degeneration. Curr. Opin. Ophthalmol. 2011, 22:199-204.
12. Conway B.R. Recent patents on ocular drug delivery systems. Recent Pat. Drug Deliv. Formul. 2008, 2:1-8.
13. Donahue S.P., et al. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial. Am. J. Ophthalmol. 2010, 150:287. (author reply 287).
14. Falkenstein I.A., et al. Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr. Eye Res. 2008, 33:599-609.
15. Fayers T. Comment on 'Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial'. Eye (Lond.) 2011, 25:820.
16. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1995, 1:27-31.
17. Gergely K., Gerinec A. Retinopathy of prematurity-epidemics, incidence, prevalence, blindness. Bratisl. Lek. Listy 2010, 111:514-517.
18. Kaplan H. Submacular surgery for choroidal neovascularisation. Br. J. Ophthalmol. 1996, 80:101.
19. Miller J.W. Treatment of age-related macular degeneration: beyond VEGF. Jpn. J. Ophthalmol. 2010, 54:523-528.
20. Nowak-Sliwinska P., et al. Vascular effects induced by anti-VEGF agents in the CAM model: effect of the DMSO. Proc SPIE. 7380a 2009.
21. Nowak-Sliwinska P., et al. Processing of fluorescence angiograms for the quantification of vascular effects induced by anti-angiogenic agents in the CAM model. Microvasc. Res. 2010, 79:21-28.
22. Nowak-Sliwinska P., et al. Vascular regrowth following photodynamic therapy in the chicken embryo chorioallantoic membrane. Angiogenesis 2010, 13:281-292.
23. Nowak-Sliwinska P., et al. Organometallic ruthenium(II)-arene compounds with anti-angiogenic activity. J. Med. Chem. 2011, 54:3895-3902.
24. Nowak-Sliwinska, P., et al., in press. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion. J. Cell. Mol. Med. doi:. [Epub ahead of print] Sep 1. doi:10.1111/j.1582-4934.2011.01440.x.
25. Sasai K., et al. Radiation therapy for ocular choroidal neovascularization (phase I/II study): preliminary report. Int. J. Radiat. Oncol. Biol. Phys. 1997, 39:173-178.
26. Scheppke L., et al. Retinal vascular permeability suppression by topical application of a novel VEGFR2/Src kinase inhibitor in mice and rabbits. J. Clin. Invest. 2008, 118:2337-2346.
27. Schmucker C., et al. Intravitreal bevacizumab (Avastin) vs. ranibizumab (Lucentis) for the treatment of age-related macular degeneration: a systematic review. Curr. Opin. Ophthalmol. 2010, 21:218-226.
28. Tamaskar I., Pili R. Update on novel agents in renal cell carcinoma. Expert Rev. Anticancer Ther. 2009, 9:1817-1827.
29. Tolentino M.J. Current molecular understanding and future treatment strategies for pathologic ocular neovascularization. Curr. Mol. Med. 2009, 9:973-981.
30. van den Bergh H. Photodynamic therapy of age-related macular degeneration: history and principles. Semin. Ophthalmol. 2001, 16:181-200.
31. Vasile E., et al. Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib. J. Thorac. Oncol. 2008, 3:912-914.
32. Xu J. Preparation, culture, and immortalization of mouse embryonic fibroblasts. Curr. Protoc. Mol. Biol. 2005, (Chapter 28, Unit 28 1).
33. Yasukawa T., et al. Intraocular sustained drug delivery using implantable polymeric devices. Adv. Drug Deliv. Rev. 2005, 57:2033-2046.